Manufacturing

Natoli engineering has made significant contributions to the pharmaceutical and nutraceutical industries. Specialising in tablet compression and encapsulation technology, innovative machines, tooling and solutions that enhance tablet and encapsulation manufacturing processes, Natoli has advanced manufacturing technologies and practices worldwide

While the drug-device combination product industry is always investing in technology that could better meet the needs of patients, governments and sponsors, the COVID-19 pandemic has accelerated the process, bringing in more outside investment and a broader range of organisations in active development

What are some trends in the mRNA space surrounding the growing desire for speed-to-market, and what hurdles are impeding the achievement of this goal?

Drug product optimisation, also known as reformulation, is a development step required by all drugs en route to market. This process takes a long time, carries a considerable cost and places significant emphasis on the predictive power of laboratory and preclinical assessments. What are some alternative pathways available to development teams?

For different binder-diluent ratios on the tablet mechanical strength, a proposed scale could serve as a ‘guiding torch’ for various formulators while designing preclinical or early phase formulations

High-titre CLD platform is an effective tool to overcome a number of challenges when developing a cell line. What are the challenges associated with developing a high-titre CLD platform and how can utilising novel technologies help overcome them?

Nanodrug carriers have gained increased attention in the pharma industry since they were used in the fight against COVID-19. What are they, and how can regulations improve the manufacture of them?

What are the differences and key design features which characterise successful tablet press performance in a continuous manufacturing setting?

IPT talks to Richard Stedman of ACG Engineering about the rise of connected and digitalised machines, and how these will improve pharmaceutical manufacturing in the future

How are current events in drug development demanding better enteric delivery solutions, and how is material science and manufacturing innovation creating a purpose-built capsule able to go the distance – all while reducing the cost and complexity of enteric development and delivery?

MUPS formulations are a widely used pharmaceutical dosage form for esomeprazole, a proton pump inhibitor. For this purpose, micropellets are coated with the active ingredient and administered in the form of tablets or capsules. An appropriate solution for the coating of micropellets is the use of fluid bed processors which utilise air flow bed technology

Since their introduction in 1956, pressurised metered dose inhalers (pMDIs) have become the dominant treatment choice for patients suffering from common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). However, unbeknown to most patients and many doctors, pMDIs account for 3.9% of NHS’s annual carbon emissions.1 Here we will discuss how formulation changes might be the answer to the pMDI-related sustainability problem